CORP-2
2014
COlchicine for Recurrent Pericarditis 2 — multiple recurrences
In 240 patients with at least two prior recurrences of pericarditis, colchicine for 6 months added to conventional anti-inflammatory therapy reduced further recurrent pericarditis compared with placebo.
Result
Efficacy: Recurrent pericarditis (intention-to-treat)RR 0.49 (95% CI 0.24-0.65) · P = 0.0009
Below 1 favours colchicine for 6 months added to conventional anti-inflammatory therapy, above 1 favours placebo.
- Absolute difference
- 20.9 points
- NNT
- 5
Absolute difference and NNT are derived from the event rates.
Also reported: NNT 5). No serious adverse events.
- Subtopic
- Recurrent pericarditis
- Design
- Double-blind, placebo-controlled RCT
- Relevance
- Important: one of several pillars.
- Cited in
- ESC 2025 Myo/Pericarditis
- Source
- Imazio M, Belli R, Brucato A, et al. Lancet. 2014;383(9936):2232-2237.doi 10.1016/S0140-6736(13)62709-9
Discussion & critique
Four northern-Italian hospitals and a predominantly idiopathic case mix, with open follow-up beyond six months limiting inference about optimal duration. It closed the last gap in the colchicine story and extends the drug to every colchicine-naïve relapse, however many have gone before.